Sugi Predict

Sugi Predict / Compounds / SCHEMBL3423947

SCHEMBL3423947

SCHEMBL3423947

COc1ccc2nc(Cl)[nH]c(=O)c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.70
▸ HSD17B10 Q99714 2/20 0.70
▸ LMNA P02545 1/20 0.70
▸ TUBB4A P04350 3/20 0.58
▸ TUBB P07437 3/20 0.58
▸ TUBA3C P0DPH7 3/20 0.58
▸ TUBA1B P68363 3/20 0.58
▸ TUBA4A P68366 3/20 0.58
▸ TUBB4B P68371 3/20 0.58
▸ TUBB3 Q13509 3/20 0.58
▸ TUBB2A Q13885 3/20 0.58
▸ TUBB8 Q3ZCM7 3/20 0.58
▸ TUBA3E Q6PEY2 3/20 0.58
▸ TUBA1A Q71U36 3/20 0.58
▸ TUBA1C Q9BQE3 3/20 0.58
▸ TUBB6 Q9BUF5 3/20 0.58
▸ TUBB2B Q9BVA1 3/20 0.58
▸ TUBB1 Q9H4B7 3/20 0.58
▸ TYMS P04818 1/20 0.51
▸ TDP2 O95551 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28096442 0.98 KDM4E (0.68) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL15666238 0.88 TUBB4A (0.56) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL11248966 0.83 KDM4E (0.72) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL29900577 0.83 KDM4E (1.00) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL1257374 0.83 KDM4E (1.00) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL8710458 0.83 KDM4E (0.72) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL30186039 0.81 KDM4E (0.65) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL6929859 0.81 KDM4E (0.65) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL28463042 0.79 TNKS (0.74) KDM4EHSD17B10LMNATUBB4ATUBB
SCHEMBL13343644 0.79 KDM4E (0.67) KDM4EHSD17B10LMNATUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608317-A4 DIPEPTIDYL PEPTIDASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2006-12-27 — — EP claimed
EP-1608317-A2 DIPEPTIDYL PEPTIDASE INHIBITORS Takeda San Diego, Inc. (US) 2005-12-28 — — EP claimed
US-20050004117-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2005-01-06 — — US claimed
WO-2004087053-A9 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX INC (US) 2004-11-11 — — WO claimed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 — — WO claimed
US-10196383-B2 Substituted quinazoline compounds and preparation and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-02-05 — — US disclosed
US-20180215737-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-08-02 — — US disclosed
EP-1608317-B1 DIPEPTIDYL PEPTIDASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2012-09-26 — — EP disclosed
EP-1608317-B1 DIPEPTIDYL PEPTIDASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2012-09-26 — — EP disclosed
US-7687625-B2 Dipeptidyl peptidase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-30 — — US disclosed
US-7687625-B2 Dipeptidyl peptidase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-30 — — US disclosed
US-7687625-B2 Dipeptidyl peptidase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-30 — — US disclosed
US-20040242568-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2004-12-02 — — US disclosed
US-20040242566-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2004-12-02 — — US disclosed
US-20040242568-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2004-12-02 — — US disclosed
US-20040242568-A1 Dipeptidyl peptidase inhibitors SYRRX, INC. 2004-12-02 — — US disclosed
WO-2004087053-A9 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX INC (US) 2004-11-11 — — WO disclosed
WO-2004087053-A9 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX INC (US) 2004-11-11 — — WO disclosed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 — — WO disclosed
WO-2004087053-A2 DIPEPTIDYL PEPTIDASE INHIBITORS SYRRX, INC. (US) 2004-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196383-B2 Substituted quinazoline compounds and preparation and uses thereof HCRTR1, HCRTR2, NPY5R KDM4E 2121/4885HSD17B10 2817/4885LMNA 2442/4885
US-20050004117-A1 Dipeptidyl peptidase inhibitors DPP9, DPP4, DPP3 KDM4E 2328/4885HSD17B10 1128/4885LMNA 4633/4885
US-20040242566-A1 Dipeptidyl peptidase inhibitors DPP9, DPP3, DPP4 KDM4E 2254/4885HSD17B10 1816/4885LMNA 4593/4885
US-20040242568-A1 Dipeptidyl peptidase inhibitors DPP9, DPP4, DPP3 KDM4E 2122/4885HSD17B10 1144/4885LMNA 4485/4885
US-20180215737-A1 SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF HCRTR1, HCRTR2, NPY5R KDM4E 2121/4885HSD17B10 2817/4885LMNA 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.